Minireviews
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 7, 2021; 27(33): 5520-5535
Published online Sep 7, 2021. doi: 10.3748/wjg.v27.i33.5520
Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future
Chiara Viganò, Giacomo Mulinacci, Andrea Palermo, Donatella Barisani, Lorena Pirola, Maria Fichera, Pietro Invernizzi, Sara Massironi
Chiara Viganò, Giacomo Mulinacci, Andrea Palermo, Lorena Pirola, Maria Fichera, Pietro Invernizzi, Sara Massironi, Division of Gastroenterology and Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza 20900, Italy
Chiara Viganò, Giacomo Mulinacci, Andrea Palermo, Lorena Pirola, Maria Fichera, Pietro Invernizzi, Sara Massironi, European Reference Network on Hepatological Diseases, San Gerardo Hospital, Monza 20900, Italy
Donatella Barisani, School of Medicine and Surgery, University of Milano-Bicocca, Monza 20900, Italy
Author contributions: Viganò C and Massironi S planned the work; Viganò C, Mulinacci G and Massironi S contributed to the design and conceptualization of the study; Mulinacci G and Palermo A wrote the first draft of the manuscript and edited figures and tables; Viganò C, Barisani D, Pirola L and Fichera M edited the subsequent versions of the manuscript; Viganò C and Massironi S revised the manuscript for relevant intellectual content; Invernizzi P corrected the final version; All the authors read and approved the final version of the manuscript.
Conflict-of-interest statement: All authors declare no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chiara Viganò, MD, Doctor, Division of Gastroenterology and Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Via G. B. Pergolesi 33, Monza 20900, Italy. c.vigano@asst-monza.it
Received: January 28, 2021
Peer-review started: January 29, 2021
First decision: May 2, 2021
Revised: May 13, 2021
Accepted: August 2, 2021
Article in press: August 2, 2021
Published online: September 7, 2021
Core Tip

Core Tip: The Severe acute respiratory syndrome coronavirus 2 pandemic has abruptly impacted the management of patients with chronic immune-mediated diseases such as inflammatory bowel diseases. In a setting of general uncertainty, gastroenterologists have faced the need to rapidly reorganize facilities and redefine priorities in inflammatory bowel disease clinical management. With an enormous research effort, accumulating evidence is deepening our understanding of the multifaceted interaction of inflammatory bowel disease care and coronavirus disease 2019. Direct and indirect effects of the pandemic will be present for some time; it is, therefore, necessary to keep recommendations constantly updated.